Double Blind Placebo Controlled Study of Outpatient Intravenous Ketamine for the Treatment of CRPS
Completed
Drexel University College of Medicine
Phase 2
2006-09-01
Complex Regional Pain Syndrome is a debilitating and extremely difficult to treat condition.
There is a large body of evidence demonstrating the therapeutic value of N-methyl-D-aspartate
(NMDA)-receptor antagonists in CRPS. The NMDA antagonist ketamine has been shown to be
effective in the treatment of CRPS, resulting in complete remission of the disease in some
patients. The purpose of this study is to evaluate intravenous outpatient infusion of
sub-anesthetic doses of ketamine for the treatment of CRPS. A thorough evaluation of this
procedure, providing information into the degree of relief and which of the constellation of
RSD symptoms are best alleviated by this procedure would result in the optimization of this
therapy for the treatment of CRPS.
Effectiveness of Atropine and Glycopyrrolate to Reduce Hyper Salivation With Ketamine Sedation
Completed
Craig J. Huang
N/A
2010-06-01
The purpose of this study is to determine if the antisialagogues (anti-salivary agents),
Atropine and Glycopyrrolate, are effective in reducing hypersalivation when sedating patients
with Ketamine for procedural sedation in the emergency department or abscess clinic. The
investigators will measure salivary flow rate by collecting oral secretions by oral
suctioning over a 30 minute time period starting with the administration of Ketamine. The
investigators hypothesize that patients who receive either atropine or glycopyrrolate will
have fewer oral secretions than patients who receive placebo.
Minimizing Nausea and Vomiting During Spinals for CS
Terminated
Kokila N Thenuwara
Phase 4
2015-05-15
In parturients undergoing Cesarean section under spinal anesthesia, co-loading of 1 liter of
crystalloids, with placing the spinal, along with administering a phenylephrine infusion and
glycopyrrolate, enables placing a spinal with minimal perioperative nausea and vomiting and
good intra and post-operative pain relief.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
